243 related articles for article (PubMed ID: 26589767)
1. Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.
Frietze KM; Roden RB; Lee JH; Shi Y; Peabody DS; Chackerian B
Cancer Immunol Res; 2016 Feb; 4(2):157-64. PubMed ID: 26589767
[TBL] [Abstract][Full Text] [Related]
2. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
[TBL] [Abstract][Full Text] [Related]
3. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
[TBL] [Abstract][Full Text] [Related]
4. Improved soluble expression of a single-chain antibody fragment in E. coli for targeting CA125 in epithelial ovarian cancer.
Sharma SK; Suresh MR; Wuest FR
Protein Expr Purif; 2014 Oct; 102():27-37. PubMed ID: 25079010
[TBL] [Abstract][Full Text] [Related]
5. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
[TBL] [Abstract][Full Text] [Related]
6. Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen.
Suzuki N; Tamada Y; Shigirahara K; Suzuki A; Susumu N; Ishida I; Aoki D
Int J Gynecol Cancer; 2008; 18(5):996-1006. PubMed ID: 18028379
[TBL] [Abstract][Full Text] [Related]
7. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
Ma J; Zhou L; Wang D
Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
[TBL] [Abstract][Full Text] [Related]
8. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).
Modrak DE; Karacay H; Cardillo TM; Newsome G; Goldenberg DM; Gold DV
Int J Oncol; 2005 Jun; 26(6):1591-6. PubMed ID: 15870874
[TBL] [Abstract][Full Text] [Related]
12. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
13. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
14. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
15. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
[TBL] [Abstract][Full Text] [Related]
16. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
[TBL] [Abstract][Full Text] [Related]
18. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.
Cramer DW; O'Rourke DJ; Vitonis AF; Matulonis UA; Dijohnson DA; Sluss PM; Crum CP; Liu BC
Clin Chem; 2010 Dec; 56(12):1889-92. PubMed ID: 20943848
[TBL] [Abstract][Full Text] [Related]
19. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]